Browse the Peptyds catalogue.

Goal-led shopping helps guided buyers compare research context, quality proof, and product fit without decoding every molecule first.

CJC-1295 and ipamorelin are talked about together because they hit two different parts of the growth-hormone axis. The interesting part of the comparison is mechanism, not which one is 'stronger'.

KLOW is an online name for GLOW (GHK-Cu, BPC-157 and TB-500) plus a fourth peptide, KPV. KPV has its own preclinical literature on inflammation; the four-peptide combination itself has no published study behind it.

Sermorelin, CJC-1295 and tesamorelin are three different points on the same GHRH map. None is EMA-authorised; only tesamorelin is an approved medicine (FDA, HIV-associated lipodystrophy) — and that matters more than any forum stack ever will.

Three GLP-1 family peptides, three different receptor mechanisms, three different regulatory positions in Europe. Here is what the published trials and the EMA EPARs actually say.

Most storage mistakes are not dramatic. They are small process failures: unclear instructions, moisture exposure, light, and avoidable temperature swings.